Cancer is a multi-factorial and dreadful disease characterized by uncontrolled growth of cells and spread of abnormal cells in the body.
1 It is the most common disease in the modern era and causes the most deaths (one in eight deaths) worldwide. Because of enduring concern across the globe, there is an everincreasing requirement for safe and effective anti-tumour agents to ght against cancer.
2a-h
1,2,3-Triazole is one of the extensively used scaffolds in pharmaceuticals and exhibits a wide range of biological activities including signicant anti-cancer proles against many human cancer cell lines. 3,4a-c,5a-f These heterocycles are bestowed with special properties like moderate dipole character, hydrogen bonding capability, rigidity, stability and can be constructed through click chemistry approach in a facile manner. 6 1,2,3-Triazoles conjugated with other pharmacophores (triazole-hybrids) known to possess potent anti-cancer activities. In this context, Kamal et al. described a new class of triazole chalcone-pyrrolo [1, 4] benzodiazepine (PBD) hybrids as inhibitors of cyclin D1 and NF-kB protein ( Fig. 1 ) which showed signicant G1 cell cycle arrest. 3 Liu et al. identied promising candidates with a broad spectrum of anti-cancer activities and low cytotoxicity against the normal cell lines HEK-293 by the synthesis of novel 1,2,3-triazoledithiocarbamate hybrids and some of them were more potent than the well-known anti-cancer drug 5-uorouracil 4a-c (Fig. 2 ). On the other hand nonsteroidal anti-inammatory drugs (NSAIDs) are the cyclooxygenase (COX) inhibitors, 7a-f and recent ndings advocate that they possess anti-cancer effects through a COX-2-independent mechanism.
7d Etodolac is a COX-2 inhibitor with analgesic and antipyretic properties and is approved by US FDA.
7f In recent years the antitumor activity of etodolac analogues against many types of cancer, such as urogenital system cancers, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and prostate cancer has been described. 7e In view of the pharmacological signicance of etodolac and triazole derivatives with reference to anticancer activity, we have attempted the synthesis of a new series of 1,2,3-triazole-etodolac hybrids and evaluated their anti-cancer properties (Fig. 3) . 
Results and discussions

Chemistry
The synthesis of a series of 1,2,3-triazole-etodolac hybrids (6a-l) carried out by using the Cu(I)-catalyzed Huisgen's 1,3-dipolar cycloaddition reaction is presented in Scheme 1.
The synthetic strategy to achieve the novel hybrid template was initiated from the reduction of acid functionality of commercially available etodolac 1 by using LAH (lithium aluminum hydride) to give the primary alcohol 2 in 92% yield.
8
The newly formed hydroxyl was transformed into azide 3 using DPPA (diphenylphosphoryl azide), TPP (triphenylphosphine) and DIAD (diisopropyl azodicarboxylate) in THF. The reaction mixture was stirred for 12 h at room temperature. The whole reaction mixture was concentrated to get the residue, which was extracted with EtOAc. The organic layer dried over anhydrous Na 2 SO 4 ltered and evaporated. The crude reaction mixture was puried by silica gel column chromatography using EtOAc/ hexane (10%) as an eluent to provide the corresponding azide 3 in 86% yield.
9 Finally, the synthesis of triazole-etodolac hybrid 6a was attempted by treating the azide 3 with the terminal alkyne 5a in the presence of CuSO 4 $5H 2 O and Lsodium ascorbate in t BuOH : H 2 O (1 : 1) at room temperature and the desired compound 6a was formed in trace amount. The prolonged reaction time and high temperature also did not improve the outcome of the reaction. Later the reaction was performed in various organic co-solvents to improve the reaction outcome 14 and the synthesis of 6a was successfully accomplished in 1 : 1 DCM : H 2 O solvent system 10 with excellent yield (86%) and the results are summarized in Table 1 (Scheme 2).
Aer optimizing the reaction conditions, we have preceded to synthesis the library of triazole-etodolac hybrids (6a-l) to prove the generality of the adopted synthetic procedure. For the 
purpose, we have synthesized desired alkynes (5a-l) by treating the commercially available phenols (4a-l) with propargyl bromide and K 2 CO 3 (Scheme 2) in good yields. 11 Finally, the Huisgen's 1,3-dipolar cycloaddition 5c,12 reaction was employed to react the azide 3 and the alkynes 5a-l to furnish the hybrid molecules 6a-l in excellent yields and the results were summarized in Table 2 .
Biology
Cytotoxicity was measured using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay, against A549 lung cancer cell lines which is a colorimetric assay.
13a ]-2,5-diphenyltetrazolium bromide) is a water-soluble yellow color tetrazolium salt and is converted to an insoluble purple formazan by cleavage of the tetrazolium ring by succinate dehydrogenase which is present in the mitochondria. The formazan product is impermeable to the cell membranes and therefore it accumulates in healthy cells. Since the reduction of MTT can only occur in metabolically active cells, the intensity of the purple color is a measure of the viability of the cells. The intensity can be measured by spectrophotometer aer dissolving formazan crystal in DMSO.
13b
The cells (5 Â 10 3 ) were seeded in each well containing 0.1 mL of medium in 96 well plates. Aer overnight incubation at 37 C in 5% CO 2 , the cells were treated with 100 mL of different test concentrations of test compounds at identical conditions with three replicates each. The cytotoxic effect of all the synthesized molecules was evaluated using doxorubicin a widely used anthracycline antibiotic and with IC 50 values of 3.3 mM on A549 as the standard reference at 25 mM doses. The cell viability was assessed aer 48 h, by adding 10 mL of MTT (5 mg mL À1 ) per well. The plates were incubated at 37 C for additional 2-4 hours. The medium was discarded and the formazan violet crystals, which were coloured for the viable cells, were dissolved in 100 mL of DMSO. The rate of color formation was measured at 570 nm in a spectrophotometer (Spectra MAX Plus; Molecular Devices; supported by SOFT max PRO-5.4). The percent inhibition of cell viability was determined with reference to the control values (without test compound). The data were normalised with the lowest and highest values and subjected to non-linear regression analysis to obtain log (concentration) vs. normalised expression (variable slope) using graph pad prism 6. The IC 50 (inhibition of cell growth) concentrations were further obtained using the graph pad prism 6.
It is apparent from the results that compounds 6e, 6f, 6h, 6j, 6l are found to be potent on lung cancer cell lines than the other (Fig. 4 , Table 3) The test compounds with >70% inhibition on cancer cell lines were chosen for the IC 50 prediction on lung cancers. It was interesting to note that compounds 6e, 6f, 6h, 6j and 6l found to possess more effect at the same dose compared to doxorubicin against A549 (lung) cancer cell line. Next, dose-response studies of active compounds were performed to calculate IC 50 value against the same cell lines. Among the whole series of title compounds (6a-l), compound 6l was found to be the most active compound with an IC 50 value of 3.29 AE 0.7 mM on lung cancer cell line (A549). The second-best compound identied in the series was 6f with IC 50 3.65 AE 0.4 value. The IC 50 values of active compounds are summarized in Table 2 .
Similar scaffolds have been reported earlier for their potent anticancer activities.
14a-c This prompted us to investigate the possible mechanism of the synthesized compounds by performing the molecular docking studies into the binding pocket of the human topoisomerase-II ATPase co-crystallized with AMP-PNP complex (TPII) [PDB:1ZXM] . 15 The water molecules, substrate cofactors were removed from the PDB le and the missing hydrogen atoms were added to the system followed by energy minimization using OPLS 2005 force eld with PolakRibiere Conjugate Gradient (PRCG) algorithm. The ligands were built using the builder feature in Maestro and each structure was prepared for docking using Ligprep 2.7 followed by molecular mechanics energy minimization using Macromodel 10.1. These geometrically optimized structures were used for Glide (grid-based ligand docking with energetics) docking using the "Extra Precision" (XP) mode of Glide 6.0.
14 As depicted in (Fig. 5b) , compound 6l showed hydrophobic interactions with active site residues Tyr 64, Ile 109, Pro 111, Val 236, Ala 237, Val 240, Pro 263, Leu 257 and interaction with other active site residues such as Asp 65, Glu 66, Asp 67, Lys 233, Lys 261 were also observed. Additionally, hydrogen bonding interactions with Tyr 244 and Asn 258 were noticed (Fig. 5c ). These results also indicate that the compound 6l is bound well within the binding site pocket of doxorubicin and almost similar binding pattern was identied. The hydrogen bonding interaction with active site residues Tyr 244 and Asn 258 was in common (Fig. 5d) . 
Conclusion
A series of 1,2,3-triazole-etodolac hybrids (6a-l) have been designed and synthesized by employing Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction. The in vitro anti-cancer activity of all the synthesized compounds against human A549 cancer cell lines was evaluated and it is found that the compounds 6e, 6f, 6h, 6j, and 6l have shown promising results in comparison with the marketed drug doxorubicin. In the series, 6l has shown very good anticancer activity with an IC 50 value of 3.29 AE 0.7 mM and second-best compound was 6f with an IC 50 value of 3.65 AE 0.4 mM. Therefore, these compounds can serve as a promising lead candidate for further study.
Experimental
General information
The reagents and materials including etodolac were of the highest commercially available purity grade and were used without any further purication. Flash column chromatography was performed on Merck silica gel 60-120 mesh. Compounds were visualized with UV light. 1 2- (1, 3, 4, 
A stirred solution of LiAlH 4 (0.38 g, 9.93 mmol) in dry THF (35 mL), was added to a solution of 2- (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indol-1-yl)acetic acid 1 (1.42 g, 4.96 mmol) in dry THF (14 mL) at 0 C. The mixture was stirred overnight at room temperature. Then reaction mixture was quenched with saturated Na 2 SO 4 solution at 0 C, the mixture was ltered through Celite, and washed with ethyl acetate. The solvent was removed to yield pure product 2 (0.33 g, 92%).
1-(2-Azidoethyl) -1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indole (3) To a stirred solution of 2- (1,8-diethyl-1,3,4,9-tetrahydropyrano [3,4-b] indol-1-yl)ethanol 2 (0.5 g, 1.75 mmol) in THF (10 mL), were DPPA (diphenylphosphoryl azide) (3.50 mmol), DIAD (di isopropyl azodicarboxylate) (5.26 mmol) and triphenylphosphine (5.26 mmol) added at 0 C. The reaction mixture was stirred overnight under nitrogen saturated atmosphere. Aer completion of reaction. The reaction mixture was poured in 100 mL water and thoroughly extracted with ethyl acetate (3 Â 50 mL). The organic layer was dried over Na 2 SO 4 , ltered and evaporation under reduced pressure. The resulting residue was puried by ash chromatography using petroleum ether : ethyl acetate (90 : 10) as the eluent, to afford the 1-(2-azidoethyl) -1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indole 3 (0.45 g, 86%) as a white solid. Chemical formula: C 17 H 22 N 4 O.
1,4-Dimethyl-2-(prop-2-yn-1-yloxy)benzene (5a)
A mixture of 2,5-dimethylphenol (0.5 g, 4.09 mmol), propargyl bromide (0.44 mL, 4.91 mmol) and K 2 CO 3 (0.84 g, 6.13 mmol) was stirred in dimethylformamide (20 mL) at room temperature. Aer completion of the reaction (TLC monitoring), the reaction mixture was diluted with EtOAc (100 mL) and washed with water (3 Â 50 mL) times. The organic phase was dried over with anhydrous Na 2 SO 4 and concentrated to dryness in vacuo. The obtained crude crystalline was puried by column chromatography to obtain a pure white solid 5a.
1-(2-(4-((2,5-Dimethylphenoxy)methyl)-1H-1,2,3-triazol-1-yl) ethyl) -1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] 
indole (6a)
To a solution of 1,4-dimethyl-2-(prop-2-yn-1-yloxy)benzene (54 mg, 0.33 mmol) 5a and 1-(2-azidoethyl) -1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indole 3 (100 mg, 0.33 mmol) in CH 2 Cl 2 (0.7 mL) and H 2 O (0.7 mL) were added CuSO 4 $5H 2 O (0.08 mg, 0.0033 mmol) and sodium ascorbate (6.6 mg, 0.033 mmol). The resulting solution was stirred for 8 h at room temperature. The reaction mixture was diluted with CH 2 Cl 2 (5 mL) and H 2 O (5 mL). The organic layer was separated, dried over Na 2 SO 4 , and concentrated. The residue was puried by ash column chromatography (hexane/EtOAc, 2 : 1) to give 1,2,3-triazole 6a as a pale green solid. Yield 86%; mp 140 C; chemical formula: 15.83, 21.41, 21.96, 23.91, 31.53, 38.04, 46.17, 60.47, 61.82, 75.44, 108.88, 112.44, 115.89, 119.91, 120.57, 121.41, 123.74, 126.21, 126.66, 129.79, 130.46, 135.00, 135.30, 136.57, 144.35, 156.23 ,3,4,9-tetrahydropyrano[3,4-b] 13.64, 22.40, 23.85, 31.43, 37.96, 46.11, 60.38, 61.43, 75.34, 107.06, 108.81, 115.84, 118.72, 119.84, 120.46, 123.58, 123.78, 126.14, 126.37, 126.62, 126.81, 127.56, 129.05, 129.41, 129.75, 134.32, 134.95, 135.27, 156.01 3254, 2958, 2898, 2870, 1709, 1632, 1511, 1462, 1259, 1215, 1177, 1078, 1051, 832, 744. 1-(2-(4-((2,4-Dibromo-6-nitrophenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethyl) -1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] indole (6c) 88, 13.25, 21.96, 23.87, 31.55, 38.11, 46.25, 60.48, 67.72, 75.40, 108.99, 115.90, 117.26, 119.88, 120.52, 121.17, 124.80, 126.22, 126.60, 127.29, 134.98, 135.25, 140.21, 141.98, 145.61, 148.22 3073, 2964, 2920, 1692, 1528, 1445, 1352, 1254, 1139, 1045, 969, 870, 810, 744, 728 . ,3,4,9-tetrahydropyrano[3,4-b] 8, 13.62, 21.90, 23.85, 31.49, 37.99, 46.12, 60.40, 61.85, 70.02, 105.13, 108.87, 115.86, 119.89, 120.49, 120.68, 121.95, 123.47, 125.15, 125.54, 125.72, 126.16, 126.38, 126.57, 127.40, 134.45, 134.95, 135.24, 153.84 ,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b] 13.19, 20.92, 23.53, 31.42, 37.55, 46.26, 61.36, 62.67, 75.34, 108.95, 113.63, 116.65, 117.82, 120.02, 121.93, 123.20, 125.63, 126.67, 130.05, 133.13, 135.27, 135.83, 157.62 2953, 2931, 2892, 1709, 1593, 1489, 1456, 1237, 1193, 963, 826, 782, 689 , 585 cm À1 . ,3,4,9-tetrahydropyrano[3,4-b] 1H), 1H), 1H), 1H) 4.61 (d, J ¼ 12.22 Hz, 1H), 4.93 (d, J ¼ 11.98 Hz, 1H), 2H), 2H), 22.50, 23.88, 29.73, 31.42, 37.87, 46.17, 60.47, 61.29, 75.41, 108.61, 114.70, 115.82, 119.81, 120.41, 121.60, 123.72, 126.18, 129.82, 135.06, 135.49, 143.62, 150.08, 158.16 , 2953 , , 2925 , , 1711 , , 1586 , , 1493 , , 1460 , , 1186 methyl)-1H-1,2,3-triazol-1-yl) ethyl) -1,3,4,9-tetrahydropyrano[3,4-b] 73, 13.61, 16.14, 21.85, 23.82, 31.33, 37.93, 46.13, 60.38, 61.68, 75.40, 108.64, 111.25, 115.72, 119.74, 120.36, 120.76, 123.27, 126.12, 126.64, 126.69, 126.82, 130.65, 134.94, 135.31, 144.05, 156.24 2958, 2920, 2893, 2871, 1739, 1689, 1591, 1498, 1460, 1378, 1241, 1050, 858, 793, 742 . ,3,4,9-tetrahydropyrano[3,4-b] 76, 13.60, 16.16, 21.87, 23.83, 31.39, 37.93, 46.12, 60.39, 61.70, 75.39, 108.71, 111.29, 115.76, 119.79, 120.40, 120.77, 123.28, 126.13, 126.62, 126.71, 126.84, 130.66, 134.95, 135.29, 144.09, 156.26 3248, 2964, 2925, 2871, 1744, 1684, 1591, 1493, 1454, 1372, 1236, 1055, 858, 787, 738 . ,3,4,9-tetrahydropyrano[3,4-b] 75, 13.60, 20.39, 22.39, 23.80, 31.37, 37.89, 46.07, 60.37, 61.45, 75.34, 108.68, 114.48 (2C) 2953, 2909, 1722, 1596, 1503, 1312, 1225, 1055, 951, 825, 787, 749, 650, 508 . ,3,4,9-tetrahydropyrano[3,4-b] 78, 13.57, 21.89, 23.78, 31.49, 37.91, 46.03, 60.37, 61.37, 75.26, 108.83, 115.84, 117.07, 119.88, 120.47, 123.59, 126.09, 126.52, 134.90, 135.19, 138.17, 143.09, 157.94 2958 , 2926 , 2893 , 1736 , 1687 , 1583 , 1523 , 1484 , 1369 , 1249 , 1227 , 1106 , 1046 13.54, 22.39, 23.79, 31.66, 37.93, 46.00, 55.95, 60.36, 62.26, 75.17, 109.09, 109.13, 112.32, 115.99, 120.05, 120.60, 124.01, 126.12, 126.37, 126.68, 130.42, 134.90, 135.09, 142.69, 149.82, 153.01, 190.88 2904 , 2854 , 1687 , 1583 , 1512 , 1463 , 1265 , 1172 , 1128 , 1013 indol-1-yl) ethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde (6l) 78, 13.58, 22.39, 23.78, 31.44, 37.85, 46.06, 60.35, 61.47, 75.21, 108.80, 114.92 (2C), 115.86, 119.87, 120.47, 123.77, 126.09, 126.50, 130.12, 131 
1-(2-(4-((4-Bromophenoxy
)methyl)-1H-1,2,3-triazol-1-yl)ethyl)- 11,8-Diethyl-1-(2-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl) ethyl)-11,8-Diethyl-1-(2-(4-((o-tolyloxy)methyl)-1H-1,2,3-triazol-1-yl) ethyl)-11,8-Diethyl-1-(2-(4-((p-tolyloxy)methyl)-1H-1,2,3-triazol-1-yl) ethyl)-11,8-Diethyl-1-(2-(4-((4-iodophenoxy)methyl)-1H-1,2,3-triazol-1- yl)ethyl)-1
